Switch maintenance treatment with gemcitabine for patients with malignant mesothelioma who do not progress after 1st line therapy with a pemetrexed-platinum combination. A randomised open label phase II study.
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Gemcitabine (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms NVALT-19
- 09 Nov 2019 Planned End Date changed from 7 Sep 2017 to 9 Jul 2017.
- 09 Nov 2019 Planned initiation date changed from 7 Sep 2013 to 9 Jul 2013.
- 28 Jan 2014 Status changed from planning to recruiting as per European Clinical Trials Database record.